Patents Assigned to BioNTech AG
  • Patent number: 10980875
    Abstract: The present invention relates to particles comprising RNA, in which the RNA is associated with a cationic polymer or lipid or with both a cationic polymer and lipid, wherein the RNA comprises a cytotoxic nucleotide or cytotoxic nucleotide analog and/or the RNA is covalently attached to a cytotoxin, pharmaceutical compositions containing said particles and pharmaceutical uses of the particles and pharmaceutical compositions. The particles of the present invention are particularly useful as an immunostimulating medicament capable to block proliferation or induce death in dividing cells such as tumor cells.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 20, 2021
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • Patent number: 10717780
    Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 21, 2020
    Assignees: BioNTech AG, Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologic an der Universitätsmedzin der Johannes Gutenberg-Universität Mainz gemcinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Patent number: 10626400
    Abstract: The present invention relates to stable low-salt aqueous formulations of particles comprising a polycation, preferably protamine, and RNA, which formulations are preferably isotonic, to pharmaceutical compositions or kits comprising such formulations and to their use in medicine. It further relates to methods for preparing the formulations of the invention and to methods for physically stabilizing particles comprising a polycation, preferably protamine, and RNA.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: April 21, 2020
    Assignee: BioNTech AG
    Inventor: Steve Pascolo
  • Patent number: 10370433
    Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Biontech AG
    Inventors: Ugur Sahin, Joycelyn Wüstehube-Lausch, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt
  • Patent number: 10302647
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: May 28, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
  • Patent number: 10253373
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 9, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Publication number: 20190062762
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Application
    Filed: September 27, 2018
    Publication date: February 28, 2019
    Applicant: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • Patent number: 10188712
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 29, 2019
    Assignees: BIONTECH AG, TRON—Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • Patent number: 10172960
    Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 8, 2019
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • Patent number: 10106800
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 23, 2018
    Assignee: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • Patent number: 10093736
    Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: October 9, 2018
    Assignees: BIONTECH AG, TRON GGMBH, UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Publication number: 20180177885
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • Publication number: 20180169236
    Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 21, 2018
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schluter, Dirk Usener, Philippe Thiel, Michael Koslowski
  • Patent number: 9944708
    Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: April 17, 2018
    Assignee: BioNTech AG
    Inventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
  • Patent number: 9910043
    Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 6, 2018
    Assignee: BioNTech AG
    Inventors: Özlem Türeci, Ugur Sahin, Gerd Helftenbein, Volker Schlüter
  • Patent number: 9730976
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: August 15, 2017
    Assignee: BioNTech AG
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • Patent number: 9636414
    Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 2, 2017
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • Patent number: 9637794
    Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 2, 2017
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Patent number: 9617321
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: April 11, 2017
    Assignees: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, BIONTECH AG
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • Patent number: 9533043
    Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: January 3, 2017
    Assignee: BioNTech AG
    Inventors: Özlem Türeci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schlüter, Dirk Usener, Philippe Thiel, Michael Koslowski